Market Overview

UPDATE: Canaccord Genuity Raises PT to $10 on Synergy Pharmaceuticals on Positive Plecanatide Data

Related SGYP
Mid-Morning Market Update: Markets Open Higher; General Electric Earnings Miss Expectations
The Week Ahead: Earnings, Earnings, And More Earnings

Canaccord Genuity reiterated its Buy rating on Synergy Pharmaceuticals (NASDAQ: SGYP) and increased its price target from $7 to $10.

Canaccord Genuity noted, "Reiterate BUY, raise target to $10 on increased probability of success for plecanatide in CIC. We see clear unmet need in chronic constipation (CIC) patients who don't respond/have AEs on current therapies. Compared to Linzess (FRX/IRWD), plecanatide may have better tolerability (no diarrhea in Phase 2a). We are raising our pNPV based target to $10 from $7, driven by increased chance of plecanatide success on today's positive proof of concept data."

Synergy Pharmaceuticals closed at $5.26 on Monday.

Latest Ratings for SGYP

Sep 2017CitigroupMaintainsSell
Jun 2017Cantor FitzgeraldInitiates Coverage OnOverweight
Apr 2017CitigroupDowngradesNeutralSell

View More Analyst Ratings for SGYP
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (SGYP)

View Comments and Join the Discussion!

Partner Center